Zanzalintinib for children with solid tumors
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This study tests an oral drug called zanzalintinib in children and teens with certain solid tumors that have come back or not responded to treatment. The goal is to see if the drug is safe and works against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are under 17 years old.
- You weigh at least 10 kilograms (about 22 pounds).
- You have a solid tumor (not lymphoma) that has returned or not responded to treatment.
- If the cancer is in the brain, there is no bleeding inside the brain.
- The tumor is not touching or invading a major blood vessel in the body.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
This trial tests a new drug called zanzalintinib for people with advanced or metastatic bone sarcomas that have not responded to standard treatments. It aims to see if the drug can help shrink or slow the growth of these tumors.
This trial studies an experimental drug called zanzalintinib for people with adenoid cystic carcinoma that has spread or come back. The goal is to see if the drug can shrink tumors or slow the disease.
This trial tests a new drug called zanzalintinib for people with advanced bladder cancer that has worsened after previous treatments. The goal is to see if zanzalintinib can help control the cancer.
This trial tests a new drug called zanzalintinib for people with advanced clear cell kidney cancer that has spread to the bones (at least 3 spots). The study wants to see if this drug can help slow down or shrink the cancer. It's for patients who have already had some prior treatments.
This trial is looking at whether a new combination of two drugs, zanzalintinib and pembrolizumab, can help people with certain types of advanced soft-tissue sarcoma that have not responded to other treatments. It aims to find out if the combination is safe and effective.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.